On July 21, 2020, ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the closing of its initial public offering of 9,775,000 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,275,000 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to ALX Oncology from the offering were approximately $185.7 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by ALX Oncology. The shares began trading on the Nasdaq Global Market on July 17, 2020, and closed on July 21, 2020, under the ticker symbol “ALXO.”

The Wilson Sonsini team that represented ALX Oncology in the offering includes:

Corporate
Ken Clark
Tony Jeffries
Michael Coke
Christina Poulsen
Kexi Wang
Mary O'Brien​

Employee Benefits and Compensation
Scott McCall
Jackie Tokuda

Tax
Myra Sutanto Shen
Jessica Yeh​​

Privacy
Matt Staples

Regulatory
David Hoffmeister
Eva Yin

Fintech
Amy Caiazza

For more information, please see ALX Oncology's press release.